NPI: 1487212551 · GREENSBORO, NC 27410 · Clinical Medical Laboratory · NPI assigned 06/03/2019
Authorized official BOWLES, CHARLES controls 20+ related entities in our dataset. Read more
| Authorized Official | BOWLES, CHARLES (VICE PRESIDENT) |
| Parent Organization | QUEST DIAGNOSTICS INCORPORATED |
| NPI Enumeration Date | 06/03/2019 |
Other providers sharing the same authorized official: BOWLES, CHARLES
| Year | Claims | Total Paid |
|---|---|---|
| 2019 | 180,499 | $2.30M |
| 2020 | 372,730 | $5.02M |
| 2021 | 317,888 | $4.22M |
| 2022 | 281,575 | $2.83M |
| 2023 | 547,851 | $4.69M |
| 2024 | 314,459 | $2.92M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 80061 | Lipid panel | 131,577 | 122,641 | $1.28M |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 57,981 | 54,059 | $1.23M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 49,791 | 43,561 | $1.19M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 49,620 | 43,443 | $1.18M |
| 80053 | Comprehensive metabolic panel | 146,038 | 134,684 | $954K |
| 84443 | Thyroid stimulating hormone (TSH) | 70,676 | 66,185 | $792K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 18,958 | 13,972 | $715K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 31,667 | 28,662 | $648K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 10,412 | 9,278 | $643K |
| 83036 | Hemoglobin; glycosylated (A1C) | 93,985 | 87,782 | $641K |
| 80050 | General health panel | 54,883 | 50,883 | $625K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 13,124 | 10,295 | $604K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 107,739 | 97,274 | $600K |
| 86003 | 6,118 | 5,387 | $492K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 66,684 | 60,033 | $442K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 18,112 | 15,549 | $378K |
| 82607 | 26,574 | 24,777 | $283K | |
| 84439 | 39,772 | 37,125 | $271K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 12,738 | 10,883 | $268K |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | 731 | 688 | $262K |
| 80074 | 6,881 | 6,316 | $262K | |
| 87088 | 38,188 | 34,473 | $257K | |
| 86480 | 7,017 | 6,408 | $248K | |
| 82728 | 22,710 | 20,840 | $221K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 6,721 | 4,543 | $199K |
| 86803 | 18,711 | 17,368 | $197K | |
| 87070 | 23,134 | 21,096 | $179K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 8,640 | 7,885 | $173K |
| 36415 | Collection of venous blood by venipuncture | 100,449 | 91,436 | $164K |
| 87186 | 22,637 | 20,420 | $162K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 28,112 | 25,309 | $153K |
| 82746 | 14,418 | 13,470 | $152K | |
| 87510 | 8,943 | 8,175 | $150K | |
| 83013 | 2,698 | 2,476 | $146K | |
| 87660 | 9,009 | 8,237 | $145K | |
| 87077 | 20,500 | 18,488 | $138K | |
| 83970 | 6,016 | 5,693 | $132K | |
| 85027 | 27,110 | 24,547 | $128K | |
| 83550 | 20,233 | 18,568 | $123K | |
| 84481 | 8,827 | 8,234 | $122K | |
| 84153 | 9,292 | 8,712 | $120K | |
| 86364 | 2,762 | 2,515 | $108K | |
| 83540 | 22,914 | 21,091 | $107K | |
| 86360 | 2,541 | 2,338 | $107K | |
| 86235 | 1,808 | 1,624 | $103K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 4,046 | 2,874 | $102K |
| 88142 | 5,848 | 4,773 | $101K | |
| 87081 | 17,379 | 15,940 | $100K | |
| 82570 | 30,443 | 28,387 | $98K | |
| 84146 | 5,215 | 4,886 | $96K | |
| 80055 | 3,752 | 3,494 | $94K | |
| 86787 | 7,312 | 6,598 | $89K | |
| 83880 | 4,299 | 3,980 | $89K | |
| 82043 | 26,074 | 24,481 | $87K | |
| 86850 | 9,301 | 8,656 | $84K | |
| 81513 | 2,858 | 2,319 | $79K | |
| 86592 | 21,343 | 19,035 | $75K | |
| 87340 | 10,140 | 9,437 | $74K | |
| 83735 | 16,225 | 14,700 | $72K | |
| 84403 | 4,204 | 3,912 | $71K | |
| 86008 | 1,349 | 1,193 | $70K | |
| 84436 | 16,647 | 15,423 | $69K | |
| 83001 | 4,661 | 4,353 | $69K | |
| 84479 | 14,362 | 13,312 | $66K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 275 | 270 | $62K |
| 86258 | 1,049 | 976 | $60K | |
| 86696 | 3,533 | 3,067 | $59K | |
| 87480 | 9,009 | 8,237 | $58K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | 224 | 198 | $57K |
| 83002 | 3,659 | 3,397 | $56K | |
| 80164 | 4,600 | 4,339 | $56K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 478 | 457 | $56K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1,177 | 1,064 | $55K |
| 86140 | 14,156 | 12,642 | $54K | |
| 82784 | 5,234 | 4,808 | $51K | |
| 82670 | 2,576 | 2,418 | $50K | |
| 84702 | 6,684 | 5,103 | $50K | |
| 80076 | 7,205 | 6,685 | $49K | |
| 82785 | 3,389 | 3,168 | $48K | |
| 88141 | 3,674 | 3,458 | $48K | |
| 86376 | 3,801 | 3,493 | $43K | |
| 83525 | 4,072 | 3,790 | $42K | |
| 87147 | 7,917 | 7,218 | $41K | |
| 87522 | Neg quan hep c or qual rna | 2,185 | 2,071 | $39K |
| 87902 | 335 | 323 | $37K | |
| 85652 | 16,641 | 14,960 | $36K | |
| 83655 | 3,992 | 3,540 | $35K | |
| 86695 | 3,054 | 2,680 | $34K | |
| 84480 | 3,433 | 3,189 | $33K | |
| 86706 | 4,354 | 4,048 | $32K | |
| 81001 | 14,545 | 12,907 | $32K | |
| 86708 | 3,372 | 3,186 | $32K | |
| 83690 | 5,871 | 5,472 | $31K | |
| 83516 | 3,916 | 2,248 | $30K | |
| 86038 | 4,426 | 3,836 | $30K | |
| 87536 | 787 | 622 | $30K | |
| 82248 | 9,007 | 7,900 | $29K | |
| 82274 | 2,169 | 2,022 | $28K | |
| 86361 | 2,752 | 2,589 | $28K | |
| 86800 | 2,137 | 2,023 | $27K | |
| 84550 | 8,974 | 8,322 | $27K | |
| 86704 | 4,187 | 3,926 | $27K | |
| 82627 | 1,570 | 1,427 | $27K | |
| 86665 | 2,339 | 1,460 | $27K | |
| 87209 | 1,825 | 1,680 | $27K | |
| 86231 | 911 | 868 | $26K | |
| 80069 | 5,343 | 4,889 | $26K | |
| 86769 | 1,026 | 722 | $26K | |
| 82105 | 2,276 | 2,151 | $26K | |
| 80081 | 802 | 666 | $25K | |
| 86160 | 1,570 | 1,446 | $25K | |
| 87150 | 840 | 824 | $24K | |
| 87075 | 3,132 | 2,848 | $24K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 196 | 190 | $24K |
| 86431 | 5,648 | 5,204 | $23K | |
| 86900 | 8,046 | 7,471 | $22K | |
| 86901 | 8,038 | 7,463 | $22K | |
| 84144 | 1,517 | 1,339 | $22K | |
| 86762 | 2,488 | 2,361 | $22K | |
| 87650 | 1,150 | 1,020 | $22K | |
| 85610 | 7,466 | 5,543 | $22K | |
| 86200 | 2,439 | 2,246 | $21K | |
| 88342 | 711 | 583 | $21K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 441 | 324 | $19K |
| 86664 | 1,501 | 1,439 | $19K | |
| 82550 | 3,676 | 3,343 | $18K | |
| 86618 | 1,374 | 1,300 | $18K | |
| 86225 | 1,843 | 1,707 | $17K | |
| 87205 | 4,818 | 4,384 | $17K | |
| 87563 | 442 | 424 | $17K | |
| 82150 | 3,853 | 3,558 | $17K | |
| 82950 | 3,920 | 3,612 | $17K | |
| 87481 | 863 | 429 | $16K | |
| 82977 | 3,287 | 3,054 | $16K | |
| 84156 | 6,073 | 5,504 | $16K | |
| 84270 | 1,198 | 1,120 | $16K | |
| 86317 | 2,485 | 1,217 | $15K | |
| 80178 | 2,342 | 2,187 | $15K | |
| 87177 | 2,465 | 2,284 | $14K | |
| 82533 | 1,051 | 997 | $13K | |
| 84402 | 948 | 897 | $13K | |
| 85379 | 1,864 | 1,708 | $13K | |
| 81596 | 276 | 261 | $13K | |
| 87449 | 1,650 | 1,275 | $12K | |
| 82140 | 1,171 | 1,065 | $12K | |
| 87427 | 1,224 | 1,143 | $12K | |
| 87338 | 1,465 | 1,385 | $12K | |
| 87045 | 1,944 | 1,832 | $11K | |
| 82951 | 915 | 869 | $11K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 499 | 400 | $11K |
| 84681 | 728 | 701 | $11K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 441 | 408 | $10K |
| 86780 | 839 | 779 | $10K | |
| 83520 | 1,143 | 982 | $10K | |
| 87800 | 1,233 | 937 | $9K | |
| 84100 | 3,527 | 3,014 | $9K | |
| 85045 | 2,967 | 2,756 | $9K | |
| 84703 | 1,376 | 1,242 | $9K | |
| 85660 | 1,411 | 1,326 | $8K | |
| 87324 | 924 | 862 | $8K | |
| 87329 | 1,014 | 941 | $8K | |
| 87046 | 1,575 | 1,148 | $8K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 44 | 40 | $8K |
| 82677 | 337 | 325 | $8K | |
| 88304 | 455 | 313 | $8K | |
| 85730 | 1,739 | 1,601 | $7K | |
| 80185 | 626 | 552 | $7K | |
| 86812 | 290 | 271 | $7K | |
| 83615 | 1,804 | 1,566 | $7K | |
| 84466 | 766 | 660 | $7K | |
| 87255 | 277 | 260 | $6K | |
| 84450 | 2,181 | 2,038 | $6K | |
| 82565 | 2,787 | 2,578 | $6K | |
| 82947 | 1,999 | 1,868 | $6K | |
| 88341 | 164 | 133 | $6K | |
| 86039 | 1,140 | 1,021 | $6K | |
| 86336 | 362 | 349 | $6K | |
| 82247 | 1,772 | 1,199 | $6K | |
| 87493 | 283 | 269 | $6K | |
| 86147 | 232 | 113 | $5K | |
| 84520 | 984 | 937 | $5K | |
| 86015 | 208 | 195 | $5K | |
| 85060 | 545 | 506 | $5K | |
| 84154 | 358 | 338 | $5K | |
| 80156 | 424 | 395 | $5K | |
| 81003 | 2,956 | 2,725 | $5K | |
| 84425 | 773 | 737 | $5K | |
| 86705 | 1,068 | 971 | $4K | |
| 85018 | 3,104 | 2,783 | $4K | |
| 82310 | 2,080 | 1,951 | $4K | |
| 82465 | 1,064 | 974 | $4K | |
| 83090 | 740 | 649 | $4K | |
| 80051 | 501 | 497 | $4K | |
| 86141 | 524 | 452 | $4K | |
| 84460 | 2,642 | 2,471 | $4K | |
| 82330 | 529 | 504 | $4K | |
| 83721 | 730 | 684 | $4K | |
| 84165 | 337 | 315 | $4K | |
| 86021 | 321 | 267 | $4K | |
| 85014 | 2,154 | 1,983 | $3K | |
| 81511 | 430 | 380 | $3K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 146 | 143 | $3K |
| 83020 | 400 | 371 | $3K | |
| 83630 | 430 | 410 | $3K | |
| 82952 | 757 | 722 | $3K | |
| 86593 | 658 | 601 | $3K | |
| 81329 | 100 | 94 | $3K | |
| 88312 | 74 | 64 | $3K | |
| 83993 | 306 | 298 | $3K | |
| 87899 | 381 | 363 | $3K | |
| 86255 | 253 | 170 | $2K | |
| 82652 | 145 | 132 | $2K | |
| 84484 | 273 | 255 | $2K | |
| 82040 | 852 | 788 | $2K | |
| 86617 | 120 | 113 | $2K | |
| 80197 | 322 | 209 | $2K | |
| 80177 | 313 | 288 | $2K | |
| 87799 | 115 | 30 | $2K | |
| 83631 | 124 | 121 | $2K | |
| 81025 | 349 | 307 | $2K | |
| 86757 | 129 | 125 | $1K | |
| 86359 | 61 | 55 | $1K | |
| 82164 | 98 | 90 | $1K | |
| 83718 | 132 | 130 | $1K | |
| 82024 | 65 | 64 | $1K | |
| 81015 | 403 | 361 | $1K | |
| 87185 | 275 | 264 | $1K | |
| 84132 | 387 | 329 | $1K | |
| 87512 | 34 | 27 | $960.25 | |
| 86334 | 138 | 125 | $950.51 | |
| 86355 | 41 | 40 | $925.78 | |
| 83921 | 162 | 151 | $891.72 | |
| 82390 | 174 | 171 | $822.96 | |
| 86381 | 28 | 26 | $792.76 | |
| 84075 | 390 | 355 | $791.94 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 17 | 13 | $771.98 |
| 84478 | 223 | 195 | $756.20 | |
| 84432 | 55 | 53 | $712.45 | |
| 84305 | 63 | 62 | $697.14 | |
| 84155 | 496 | 455 | $680.14 | |
| 86304 | 71 | 65 | $636.47 | |
| 86870 | 31 | 28 | $633.51 | |
| 82103 | 113 | 113 | $629.30 | |
| 86709 | 97 | 84 | $585.68 | |
| 86308 | 124 | 116 | $562.66 | |
| 83519 | 73 | 40 | $550.64 | |
| 84630 | 97 | 95 | $545.56 | |
| 86146 | 28 | 12 | $511.89 | |
| 86735 | 40 | 40 | $501.23 | |
| 82107 | 26 | 26 | $466.04 | |
| 86644 | 29 | 28 | $448.00 | |
| 86765 | 39 | 39 | $437.70 | |
| 86645 | 27 | 26 | $434.24 | |
| 82088 | 26 | 25 | $421.93 | |
| 84445 | 26 | 26 | $418.39 | |
| 82378 | 31 | 30 | $411.02 | |
| 82542 | 27 | 25 | $397.80 | |
| 85007 | 147 | 128 | $391.45 | |
| 84244 | 31 | 30 | $369.22 | |
| 87807 | 29 | 26 | $357.00 | |
| 87210 | 99 | 83 | $356.33 | |
| 84295 | 222 | 198 | $350.43 | |
| 85041 | 282 | 277 | $337.57 | |
| 86357 | 12 | 12 | $329.17 | |
| 87517 | 14 | 14 | $328.30 | |
| 86036 | 37 | 28 | $323.81 | |
| 82525 | 48 | 48 | $267.18 | |
| 84134 | 31 | 27 | $258.37 | |
| 83021 | 48 | 46 | $245.32 | |
| 84207 | 15 | 15 | $224.80 | |
| 88300 | 26 | 26 | $215.53 | |
| 83498 | 14 | 14 | $209.76 | |
| 84590 | 41 | 41 | $206.08 | |
| 86886 | 45 | 40 | $203.03 | |
| 88112 | 16 | 12 | $194.68 | |
| 83014 | 37 | 31 | $171.49 | |
| 87328 | 27 | 24 | $159.76 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | 1,329 | 1,261 | $139.18 |
| 83695 | 26 | 25 | $131.11 | |
| 80175 | 26 | 26 | $131.00 | |
| 83835 | 14 | 13 | $126.22 | |
| 87040 | 15 | 13 | $126.06 | |
| 81243 | 12 | 12 | $118.94 | |
| 85651 | 25 | 25 | $103.54 | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 111 | 109 | $91.97 |
| 82787 | 12 | 12 | $73.56 | |
| 82374 | 12 | 12 | $11.90 | |
| 82435 | 12 | 12 | $11.20 | |
| 36416 | 36 | 26 | $0.23 | |
| G0307 | Complete (cbc), automated (hgb, hct, rbc, wbc; without platelet count) | 59 | 56 | $0.00 |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | 18 | 17 | $0.00 |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | 93 | 91 | $0.00 |